Northern (& Bristol) Prostate Cancer Collaborative - Manchester component

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Prostate cancer is the most common male tumour. Its incidence is increasing because of improved diagnosis and an aging population. Presently, neither populations at risk, nor men with prostate cancer at high risk of future progression, can be identified accurately, leading to unsuitable treatment for some men. Future prospects for improving the morbidity and impact of prostate cancer in the EC are exciting. Our team has the critical mass and expertise to address the important questions in prostate cancer. By means of post-genomic and proteomic approaches, molecular epidemiology and clinical research, we intend to: refine treatment protocols based on molecular characterisation of tumours; to produce novel treatments based on a better understanding of the mechanisms underpinning progression and androgen resistance; and to identify high risk-risk populations through study of gene-environment interactions. These approaches, and studies of gene and protein expression in advanced, incurable prostate cancer will generate targets for development of new treatments and diagnostic agents that will be exploited through partnership with industry.